TEC02-Hospital Pharmacotherapeutic Follow-up
Advanced Therapies and Biomedical Technologies / IBS-TEC02 / Consolidated
Research group of the pharmacy service of the Virgen de las Nieves Hospital located on the 4th floor of the Materno Infantil along with the Chair of Pharmaceutical Care of the Faculty of Pharmacy of the University of Granada. This service has a pharmacogenetics laboratory where the experimental part of the lines of research detailed below is carried out.
Research lines
- Personalized medicine through pharmacogenetics in patients undergoing treatment with biological therapy for oncological, dermatological, digestive rheumatological diseases and multiple sclerosis.
- Pharmacotherapeutic follow-up and pharmacokinetic monitoring in patients with serious infections treated with antibiotics.
- Association study of vitamin D polymorphisms in the susceptibility to develop diseases.
- Pharmacoeconomic analysis of hospital treatments.
- Drug safety studies.
- Influence of vitamin D polymorphisms in the response to drugs.
Keywords
Pharmacogenetics, Pharmacotherapeutic Follow-up, Biological Therapy, Antibiotics.
ELIZABETH SPRUCE SPARTA
LAURA ELENA PINEDA LANCHEROS
MARIA ROSA CANTUDO ACCOUNT
CRISTINA PEREZ-RAMIREZ
NOELIA MARQUEZ PETE
FERNANDO MARTINEZ MARTINEZ
CRISTINA MEMBRIVE JIMENEZ
MERITXELL SALAZAR BRAVO
CAROLINA ALARCON PAYER
PILAR AZNARTE PADIAL
BARBARA CANCEL TEN
ABDELALI DADDAOUA
Monica Ferrit Martin
CARLOS GARCIA COLLADO
DESIRE GONZALEZ CALLEJAS
ALBERTO JIMENEZ-MORALES
CRISTINA LUCIA DAVILA FAJARDO
Metformin-NSAIDs Molecular Salts: A Path towards Improved Oral Bioavailability and Stability
PHARMACEUTICS, 2023;
FI: 5,4; Q1
Enhanced NSAIDs Solubility in Drug-Drug Formulations with Ciprofloxacin
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023;
FI: 6,208; Q1
Polymorphisms in VDR, CYP27B1, CYP2R1, GC and CYP24A1 Genes as Biomarkers of Survival in Non-Small Cell Lung Cancer: A Systematic Review
NUTRIENTS, 2023;
FI: 5,9; Q1
Association of Single-Nucleotide Polymorphisms in Capecitabine Bioactivation Pathway with Adjuvant Therapy Safety in Colorectal Cancer Patients
PHARMACEUTICS, 2023;
FI: 5,4; Q1
ABCC1, ABCG2 and FOXP3: Predictive Biomarkers of Toxicity from Methotrexate Treatment in Patients Diagnosed with Moderate-to-Severe Psoriasis
BIOMEDICINE, 2023;
FI: 4,7; Q2
Effect of Single Nucleotide Polymorphisms in the Vitamin D Metabolic Pathway on Susceptibility to Non-Small-Cell Lung Cancer
NUTRIENTS, 2022;
FI: 6,706; Q1
Genetic Polymorphisms in VEGFR Coding Genes (FLT1/KDR) on Ranibizumab Response in High Myopia and Choroidal Neovascularization Patients
PHARMACEUTICS, 2022;
FI: 6,525; Q1
Hypoxia-Inducible Factor-1 Alpha Expression Is Predictive of Pathological Complete Response in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy
CANCER, 2022;
FI: 6,575; Q1
Vitamin D-Related Single Nucleotide Polymorphisms as Risk Biomarker of Cardiovascular Disease
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022;
FI: 6,208; Q1
Impact of Genetic Polymorphisms and Biomarkers on the Effectiveness and Toxicity of Treatment of Chronic Myeloid Leukemia and Acute Myeloid Leukemia
JOURNAL OF PERSONALIZED MEDICINE, 2022;
FI: 3,508; Q2
Ecuador and Spain community pharmacies. legal aspects
Ars Pharmaceutica, 2021;
Cost of Venous Thromboembolic Disease in Patients with Lung Cancer: COSTECAT Study
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021;
FI: 3,39; Q1
Clinical Application of Pharmacogenetic Markers in the Treatment of Dermatologic Pathologies
PHARMACEUTICALS, 2021;
FI: 5,863; Q1
Furosemide/Non-Steroidal Anti-Inflammatory Drug-Drug Pharmaceutical Solids: Novel Opportunities in Drug Formulation
CRYSTALS, 2021;
FI: 2,589; Q2
Association between polymorphisms in the vitamin D receptor and susceptibility to multiple sclerosis
PHARMACOGENETICS AND GENOMICS, 2021;
FI: 2,089; Q4
Clinical impact of a pharmacist-led medication review with follow up for aged polypharmacy patients: A cluster randomized controlled trial
PHARMACY PRACTICE-GRANADA, 2020;
Collaborative health service planning: A stakeholder analysis with social network analysis to develop a community pharmacy service
RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY, 2020;
FI: 2,844; Q1
Developing robust protein analysis profiles to identify bacterial acid phosphatases in genomes and metagenomic libraries.
ENVIRONMENTAL MICROBIOLOGY, 2020;
FI: 4,933; Q1
Acute coronary syndrome and recurrent colitis as immune-related adverse events in a lung cancer patient
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020;
FI: 1,826; Q3
Association of ABCB1 and VEGFA gene polymorphisms with breast cancer susceptibility and prognosis
PATHOLOGY RESEARCH AND PRACTICE, 2020;
FI: 2,05; Q3
Impact of single nucleotide polymorphisms on the efficacy and toxicity of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients.
MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, 2019;
FI: 6,081; D1
Evolution of the phenolic compounds profile of olive leaf extract encapsulated by spray-drying during in vitro gastrointestinal digestion
FOOD CHEMISTRY, 2019;
FI: 5,399; D1
Cohort Profile: Design and methods of the PREDIMED-Plus randomized trial
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2019;
FI: 7,339; D1
Supercritical CO2 extraction of bioactive compounds from Hibiscus sabdariffa
JOURNAL OF SUPERCRITICAL FLUIDS, 2019;
FI: 3,481; Q1
FCGR2A / FCGR3A Gene Polymorphisms and Clinical Variables as Predictors of Response to Tocilizumab and Rituximab in Patients With Rheumatoid Arthritis
JOURNAL OF CLINICAL PHARMACOLOGY, 2019;
FI: 2,915; Q2
Impact of DNA repair, folate and glutathione gene polymorphisms on risk of non-small cell lung cancer
PATHOLOGY RESEARCH AND PRACTICE, 2018;
FI: 1,466; Q3
Impact of a pharmaceutical care program for patients with chronic disease initiated at the emergency department on drug-related negative outcomes: a randomized controlled trial
EUROPEAN JOURNAL OF HOSPITAL PHARMACY-SCIENCE AND PRACTICE, 2018;
FI: 0,538; Q4
Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer.
MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, 2017;
FI: 5,5; D1
Free software to analyze the clinical relevance of drug interactions with antiretroviral agents (SIMARV (R)) in patients with HIV / AIDS
RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY, 2017;
FI: 2,403; Q1
Interleukins as new prognostic genetic biomarkers in non-small cell lung cancer.
SURGICAL ONCOLOGY-OXFORD, 2017;
FI: 3,304; Q1
Cytokine single-nucleotide polymorphisms and risk of non-small-cell lung cancer.
PHARMACOGENETICS AND GENOMICS, 2017;
FI: 2,184; Q2
Secukinumab is the most efficient treatment for achieving clear skin in psoriatic patients: a cost-consequence study from the Spanish National Health Service
JOURNAL OF DERMATOLOGICAL TREATMENT, 2017;
FI: 1,89; Q2
Relevance of BRAF and NRAS mutations in the primary tumor and metastases of papillary thyroid carcinomas.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2016;
FI: 2,76; D1
Gene polymorphisms as predictors of response to biological therapies in psoriasis patients.
PHARMACOLOGICAL RESEARCH, 2016;
FI: 4,816; Q1
Genetic and clinical biomarkers of tocilizumab response in patients with rheumatoid arthritis.
PHARMACOLOGICAL RESEARCH, 2016;
FI: 4,816; Q1
Pharmacogenetic predictors of toxicity to platinum-based chemotherapy in non-small cell lung cancer patients.
PHARMACOLOGICAL RESEARCH, 2016;
FI: 4,816; Q1
ABCB1 C3435T gene polymorphism as a potential biomarker of clinical outcomes in HER2-positive breast cancer patients.
PHARMACOLOGICAL RESEARCH, 2016;
FI: 4,816; Q1
Extrapolation of acenocoumarol pharmacogenetic algorithms
VASCULAR PHARMACOLOGY, 2015;
FI: 3,635; Q1
MET / HGF targeted drugs as potential therapeutic strategies in non-small cell lung cancer
PHARMACOLOGICAL RESEARCH, 2015;
FI: 4,408; Q1
Differences in cancer drug assessment between Spain and the United Kingdom
EUROPEAN JOURNAL OF CANCER, 2015;
FI: 5,417; Q1
Granulocyte colony-stimulating factors as prophylaxis against febrile neutropenia
SUPPORTIVE CARE IN CANCER, 2015;
FI: 2,364; Q1
Trends in survival of multiple myeloma: A thirty-year population-based study in a single institution.
CANCER EPIDEMIOLOGY, 2015;
FI: 2,711; Q1
Search for genetic and epigenetic markers in response to antiaggregant treatment in patients with ACS-stent for its application through a prescription algorithm
Funder: STATE RESEARCH AGENCY
File number: PID2020-113823RB-I00
Execution time: 01/09/2021 - 31/08/2024
IP: CRISTINA LUCIA DAVILA FAJARDO
Decision algorithm for prevention of cardiovascular events based on NGS technology for patients with acute coronary syndrome undergoing percutaneous coronary intervention. functional studies
Funder: COUNCIL OF ECONOMIC TRANSFORMATION, INDUSTRY, KNOWLEDGE AND UNIVERSITIES
File number: PY20_01155
Execution time: 01/06/2021 - 31/12/2022
IP: CRISTINA LUCIA DAVILA FAJARDO
Pharmacotherapeutic follow-up of people with stage 5 chronic kidney disease in renal replacement therapy: clinical and humanistic impact: NefroDáder Project
Funder: ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH RESEARCH MANAGEMENT OF SEVILLE
Type of test: INDEPENDENT POST-AUTHORIZATION STUDY
Execution time: 21/09/2020 - 30/12/2023
PI: ALBERTO JIMENEZ MORALES